Health economic analysis traditionally relies on patient derived questionnaire data, routine datasets, and outcomes data from experimental randomised control trials and other clinical studies, which are generally used as stand-alone datasets.
In large datasets where outcomes are not rare, full multivariate models are superior to parsimonious models, because they provide better control for residual confounding compared to more restricted models.
In the datasets and outcomes studied, and for the specific conventional analyses we used, we have shown that use of the bootstrap does not lead to different p-values, SE and CI estimates compared to conventional methods.
Almost all datasets of outcome variables and their changes from baseline were proved to be normally distributed according to either Kolmogorov-Smirnov or Shapiro-Wilk test.
Differences between the microarray datasets, varying outcome information, and incomplete control of confounding by prognostic factors may limit interpretation of these findings; however, we attempted to control for patient and tumour heterogeneity between these studies by performing two analyses: a random-effects and a fixed-effects meta-analysis.
Ambler et al (2007) compared different methods using a large dataset investigating outcome after cardiac surgery.
For the van de Vijver dataset, he outcome variable (survival) is right censored, i.e., if a patient survives for > =5 years, she is considered to have good prognosis, else bad prognosis.
In our experiments, we examine three different applications of the ccSVM in bioinformatics: microarray cross-platform comparability on a simulated dataset, disease outcome prediction with correction for various kinds of side information and phenotype prediction with population structure correction.
The other datasets showed satisfactory outcomes with validities close to the desired 0.8 and efficiencies ranging from 0.6 to 0.9 in the internal validations on the training data.
Empowering pervasive computing, integrating inference models, and leveraging network solutions; Optimizing data re-use strategies; Validating the significance of evidences by cross testing and cross-referencing across models and against datasets; Generating patient outcomes from large sets of features.
